1
Clinical Trials associated with Allogeneic CAR19 regulatory T cells(Masonic Cancer Center, University of Minnesota)Phase I/II First-in-Human Trial With CAR19 Regulatory T Cells (CAR19-tTreg) in Adults With Relapsed/Refractory CD19+ B Acute Lymphocytic Leukemia
This is a single-center, single-arm, interventional phase I/II trial to evaluate the safety profile and potential efficacy of allogeneic CAR19 regulatory T cells (CAR19-tTreg) in adults with relapsed/refractory (R/R) CD19+ B Acute Lymphocytic Leukemia (B-ALL).
The study consists of two components. The dose finding component is a modified version of a Phase I trial and the extended component is a modified Phase II trial.
100 Clinical Results associated with Allogeneic CAR19 regulatory T cells(Masonic Cancer Center, University of Minnesota)
100 Translational Medicine associated with Allogeneic CAR19 regulatory T cells(Masonic Cancer Center, University of Minnesota)
100 Patents (Medical) associated with Allogeneic CAR19 regulatory T cells(Masonic Cancer Center, University of Minnesota)
100 Deals associated with Allogeneic CAR19 regulatory T cells(Masonic Cancer Center, University of Minnesota)